Becton Dickinson 将来の成長

Future 基準チェック /36

Becton Dickinson利益と収益がそれぞれ年間15.3%と5.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に21.9% 14.1%なると予測されています。

主要情報

15.3%

収益成長率

14.1%

EPS成長率

Medical Equipment 収益成長	0%
収益成長率	5.7%
将来の株主資本利益率	21.9%
アナリストカバレッジ	Good
最終更新日	21 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BMV:BDX * - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2027	24,023	2,837	3,904	5,273	7
9/30/2026	23,015	2,570	3,499	4,911	14
9/30/2025	21,968	2,354	2,997	3,934	15
9/30/2024	20,171	2,003	3,028	4,486	15
6/30/2024	19,828	1,459	3,221	3,944	N/A
3/31/2024	19,716	1,364	3,025	3,760	N/A
12/31/2023	19,492	1,265	2,649	3,431	N/A
9/30/2023	19,372	1,470	2,115	2,989	N/A
6/30/2023	19,046	1,582	1,743	2,638	N/A
3/31/2023	18,809	1,556	1,009	1,966	N/A
12/31/2022	18,738	1,486	1,361	2,359	N/A
9/30/2022	18,870	1,545	1,661	2,634	N/A
6/30/2022	18,958	1,412	1,465	2,575	N/A
3/31/2022	18,924	1,430	2,041	3,141	N/A
12/31/2021	18,534	1,079	2,620	3,751	N/A
9/30/2021	19,131	1,514	3,453	4,647	N/A
6/30/2021	19,066	1,486	4,222	5,177	N/A
3/31/2021	18,313	1,379	4,150	5,064	N/A
12/31/2020	18,207	1,507	3,476	4,359	N/A
9/30/2020	16,074	245	2,728	3,497	N/A
6/30/2020	16,917	786	2,474	3,429	N/A
3/31/2020	17,414	923	2,509	3,499	N/A
12/31/2019	17,355	760	2,835	3,798	N/A
9/30/2019	17,290	1,081	2,373	3,330	N/A
6/30/2019	17,108	784	2,359	3,265	N/A
3/31/2019	17,036	926	2,009	2,875	N/A
12/31/2018	17,063	894	1,906	2,790	N/A
9/30/2018	15,983	159	1,970	2,865	N/A
6/30/2018	14,747	621	1,837	2,685	N/A
3/31/2018	13,503	-99	N/A	2,527	N/A
12/31/2017	12,251	294	N/A	2,555	N/A
9/30/2017	12,093	1,030	N/A	2,550	N/A
6/30/2017	12,158	759	N/A	2,129	N/A
3/31/2017	12,321	1,314	N/A	2,579	N/A
12/31/2016	12,419	1,309	N/A	2,411	N/A
9/30/2016	12,483	976	N/A	2,559	N/A
6/30/2016	12,312	1,139	N/A	2,532	N/A
3/31/2016	12,234	810	N/A	2,236	N/A
12/31/2015	11,217	688	N/A	1,907	N/A
9/30/2015	10,282	695	N/A	1,730	N/A
6/30/2015	9,410	815	N/A	1,591	N/A
3/31/2015	8,448	1,079	N/A	1,492	N/A
12/31/2014	8,468	1,150	N/A	1,677	N/A
9/30/2014	8,446	1,185	N/A	1,746	N/A
6/30/2014	8,345	974	N/A	1,876	N/A
3/31/2014	8,239	941	N/A	1,830	N/A
12/31/2013	8,169	930	N/A	1,626	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BDX *の予測収益成長率 (年間15.3% ) は貯蓄率 ( 8.1% ) を上回っています。

収益対市場: BDX *の収益 ( 15.3% ) はMX市場 ( 11.7% ) よりも速いペースで成長すると予測されています。

高成長収益: BDX *の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: BDX *の収益 ( 5.7% ) MX市場 ( 7.3% ) よりも低い成長が予測されています。

高い収益成長: BDX *の収益 ( 5.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BDX *の自己資本利益率は、3年後には高くなると予測されています ( 21.9 %)

Becton Dickinson 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Recent updates

Third quarter dividend of US$1.04 announced

Third quarter dividend of US$1.04 announced

Becton, Dickinson and Company Has Declares A Quarterly Dividend, Payable on December 31, 2024

Becton, Dickinson and Company Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations

Becton, Dickinson and Company Announces New Robotics Solution to Automate, Standardize Single-Cell Research

Becton, Dickinson and Company to Report Q4, 2024 Results on Nov 07, 2024

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Upcoming dividend of US$0.95 per share

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Third quarter 2024 earnings released: EPS: US$1.68 (vs US$1.37 in 3Q 2023)

Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024

Second quarter dividend of US$0.95 announced

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024

Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024

BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool

Senior VP recently sold Mex$1.3m worth of stock

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Upcoming dividend of US$0.95 per share

Insider recently sold Mex$13m worth of stock

Second quarter dividend of US$0.95 announced

Second quarter dividend of US$0.95 announced

Second quarter 2024 earnings released: EPS: US$1.86 (vs US$1.54 in 2Q 2023)

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Insider recently sold Mex$6.8m worth of stock

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024

Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.

Becton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024

Senior VP recently sold Mex$1.1m worth of stock

Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

Upcoming dividend of US$0.95 per share

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

First quarter dividend of US$0.95 announced

First quarter 2024 earnings released: EPS: US$0.97 (vs US$1.71 in 1Q 2023)

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Fourth quarter dividend of US$0.95 announced

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024

Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024

Insider recently sold Mex$5.0m worth of stock

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection Device

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw Technology

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023

Insider recently sold Mex$2.2m worth of stock

Board Member recently sold Mex$4.0m worth of stock

Insider recently sold Mex$6.2m worth of stock

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: EPS: US$1.37 (vs US$1.29 in 3Q 2022)

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Upcoming dividend of US$0.91 per share at 1.5% yield

Second quarter 2023 earnings released

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Upcoming dividend of US$0.91 per share at 1.6% yield

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

First quarter 2023 earnings released: EPS: US$1.71 (vs US$2.30 in 1Q 2022)

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes